Subscribe to Search results

Dr Pool realised that plastic bags could be used in a closed, sterile system to hold separated out cryoprecipitate, which could then be stored and used by blood banks.

Published on:

Dr Peter Jones wrote that "Cryoprecipitate is now the method of choice in treating bleeding episodes in patients with haemophilia, but, when not available, adequate therapy with fresh frozen plasma is possible and can be made relatively safe."

Published on:

Dr Jones wrote that "Thirty years ago most haemophiliacs died of exsanguination in childhood. Today they can expect to live a normal life-span."

Published on:

Dr Jones attributed the fact that people with haemophilia were expected to live a normal life-span to the identification of Factor 8, the organisation of the blood transfusion services post war - and to cryoprecipitate.

Published on:

Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients.

Published on:

The 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals.

Published on:

Commercial concentrate was to be used in the management of severe bleeds, not as first choice, but as second best to cryoprecipitate. Dr Jones stated: "When insufficient cryoprecipitate is available."

Published on:

By 1977 Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients - talking of both cryoprecipitate and freeze-dried concentrates in the same breath as having made a difference, but then pointing out that Factor 8 concentrate was not without its problems, principal among which was that it was a significant cause of hepatitis.

Published on:

In her expert witness report regarding the HIV litigation, Dr Mayne described the advantages of cryoprecipitate, amongst which were "efficacy, low donor exposure, simplicity of manufacture" set against some disadvantages; its discovery "transformed Haemophilia treatment".

Published on:

Even by 1990, after concentrates had become very widely used, Dr Mayne summarised her opinion as being "the selection of mode of treatment depends upon the category or type of patient concerned. In respect that cryoprecipitate and Factor VIII concentrates are both efficacious treatments, preference of the one over the other depends on the age, the severity of the haemophilia and whether the patient is on a self-treatment programme, or requires major or minor surgery."

Published on:

In a profile of haemophilia management in Northern Ireland, Dr Mayne described how "In 1967 a milestone occurred; a revolutionary concentrate was produced called 'cryoprecipitate'."

Published on:

A witness told the Inquiry that such were the effects of his haemophilia before he went to Lord Mayor Treloar's College that: "I think at age six I went to school for three days in the year. And then in the following year, I think I probably went for about nine days."

Published on:

Although the 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals, by 1975 around 50% of haemophilia centres were using cryoprecipitate for some part of their home therapy programmes.

Published on:

The UK Haemophilia Centre Directors Home Therapy Working Party had access to figures showing an increased use for that year of cryoprecipitate in home therapy.

Published on:

A paper by Dr Biggs published in the British Journal of Haematology in 1974 showed that the mean pool size in 1971 for Factor 8 was 192 donations.

Published on:

The paper by Dr Biggs had first been presented in draft to the Expert Group on the Treatment of Haemophilia on 20 March 1973, so by 1974, even more than in 1973, it may not have represented up-to-the-minute views in the light of greater experience with factor concentrates.

Published on:

Professor Charles Hay in evidence acknowledged that by contrast with Manchester and Liverpool where there was little prophylaxis during the 1980s, centres such as Newcastle and Treloar's adopted it much earlier.

Published on:

Professor Charles Hay in evidence acknowledged that there was little prophylaxis during the 1980s and referenced the Prophylaxis and the Home Therapy Working Parties' audit of their roll out of home therapy which showed that it was slower than he had realised.

Published on:

An article by Dr Rizza and Dr Spooner reported that during 1976-80 the average ages of the patients with haemophilia who died were 46.7 years in the haemophilia A group and 48.3 years in the haemophilia B group. Comparable figures for 1969-74 were 42.3 years and 33.6 years, respectively.

Published on:

As late as January 1980 at a meeting of haemophilia reference centre directors the matter of "cryoprecipitate versus factor VIII concentrates for home therapy had been discussed at considerable length and the Reference Centre Directors had agreed that factor VIII concentrates were preferred for home therapy."

Published on: